Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization

J. Urbancsek, E. Witthaus

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: To establish whether time to down-regulation and pregnancy and live birth rates were different when buserelin acetate was started in the midluteal phase or early follicular phase in IVF-ET patients. Design: Prospective, controlled, randomized, parallel-group multicenter clinical study. Setting: Women attending seven infertility clinics. Patients: One hundred twenty-four women with tubal or unexplained infertility with normal menstruation and fertile partners. Interventions: Intranasal buserelin acetate started in the midluteal or early follicular phase combined with standard hMG and hCG stimulation after achievement of down-regulation. Established IVF-ET methods. Main Outcome Measures: Duration of down- regulation; clinical pregnancy and live birth rates. Results: Kaplan-Meier estimations of the duration of down-regulation were 15.5 days when buserelin acetate was started in the early follicular phase (127 cycles) and 14.6 days when it was started in the midluteal phase (96 cycles). This difference was statistically significant. The pregnancy rates per first treatment cycle, treatment cycle, oocyte retrieval, and ET were significantly higher when buserelin acetate was started in the midluteal phase. The live birth rates were also higher, but only significantly so for the rate per first treatment cycle. Conclusions: Clinical pregnancy and live birth rates are better when buserelin acetate is started in the midluteal phase rather than the early follicular phase before hMG and hCG stimulation in preparation for IVF-ET.

Original languageEnglish
Pages (from-to)966-971
Number of pages6
JournalFertility and Sterility
Volume65
Issue number5
Publication statusPublished - 1996

Fingerprint

Buserelin
Follicular Phase
Fertilization in Vitro
Gonadotropins
Gonadotropin-Releasing Hormone
Pregnancy Rate
Down-Regulation
Infertility
Oocyte Retrieval
Menstruation
Birth Rate
Live Birth
Multicenter Studies
Therapeutics
Outcome Assessment (Health Care)

Keywords

  • Buserelin
  • combined treatment
  • early follicular phase administration
  • GnRH analog
  • IVF- ET
  • midluteal phase administration

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

@article{ca943b0a4b084335b5b63bb037c2a293,
title = "Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization",
abstract = "Objective: To establish whether time to down-regulation and pregnancy and live birth rates were different when buserelin acetate was started in the midluteal phase or early follicular phase in IVF-ET patients. Design: Prospective, controlled, randomized, parallel-group multicenter clinical study. Setting: Women attending seven infertility clinics. Patients: One hundred twenty-four women with tubal or unexplained infertility with normal menstruation and fertile partners. Interventions: Intranasal buserelin acetate started in the midluteal or early follicular phase combined with standard hMG and hCG stimulation after achievement of down-regulation. Established IVF-ET methods. Main Outcome Measures: Duration of down- regulation; clinical pregnancy and live birth rates. Results: Kaplan-Meier estimations of the duration of down-regulation were 15.5 days when buserelin acetate was started in the early follicular phase (127 cycles) and 14.6 days when it was started in the midluteal phase (96 cycles). This difference was statistically significant. The pregnancy rates per first treatment cycle, treatment cycle, oocyte retrieval, and ET were significantly higher when buserelin acetate was started in the midluteal phase. The live birth rates were also higher, but only significantly so for the rate per first treatment cycle. Conclusions: Clinical pregnancy and live birth rates are better when buserelin acetate is started in the midluteal phase rather than the early follicular phase before hMG and hCG stimulation in preparation for IVF-ET.",
keywords = "Buserelin, combined treatment, early follicular phase administration, GnRH analog, IVF- ET, midluteal phase administration",
author = "J. Urbancsek and E. Witthaus",
year = "1996",
language = "English",
volume = "65",
pages = "966--971",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization

AU - Urbancsek, J.

AU - Witthaus, E.

PY - 1996

Y1 - 1996

N2 - Objective: To establish whether time to down-regulation and pregnancy and live birth rates were different when buserelin acetate was started in the midluteal phase or early follicular phase in IVF-ET patients. Design: Prospective, controlled, randomized, parallel-group multicenter clinical study. Setting: Women attending seven infertility clinics. Patients: One hundred twenty-four women with tubal or unexplained infertility with normal menstruation and fertile partners. Interventions: Intranasal buserelin acetate started in the midluteal or early follicular phase combined with standard hMG and hCG stimulation after achievement of down-regulation. Established IVF-ET methods. Main Outcome Measures: Duration of down- regulation; clinical pregnancy and live birth rates. Results: Kaplan-Meier estimations of the duration of down-regulation were 15.5 days when buserelin acetate was started in the early follicular phase (127 cycles) and 14.6 days when it was started in the midluteal phase (96 cycles). This difference was statistically significant. The pregnancy rates per first treatment cycle, treatment cycle, oocyte retrieval, and ET were significantly higher when buserelin acetate was started in the midluteal phase. The live birth rates were also higher, but only significantly so for the rate per first treatment cycle. Conclusions: Clinical pregnancy and live birth rates are better when buserelin acetate is started in the midluteal phase rather than the early follicular phase before hMG and hCG stimulation in preparation for IVF-ET.

AB - Objective: To establish whether time to down-regulation and pregnancy and live birth rates were different when buserelin acetate was started in the midluteal phase or early follicular phase in IVF-ET patients. Design: Prospective, controlled, randomized, parallel-group multicenter clinical study. Setting: Women attending seven infertility clinics. Patients: One hundred twenty-four women with tubal or unexplained infertility with normal menstruation and fertile partners. Interventions: Intranasal buserelin acetate started in the midluteal or early follicular phase combined with standard hMG and hCG stimulation after achievement of down-regulation. Established IVF-ET methods. Main Outcome Measures: Duration of down- regulation; clinical pregnancy and live birth rates. Results: Kaplan-Meier estimations of the duration of down-regulation were 15.5 days when buserelin acetate was started in the early follicular phase (127 cycles) and 14.6 days when it was started in the midluteal phase (96 cycles). This difference was statistically significant. The pregnancy rates per first treatment cycle, treatment cycle, oocyte retrieval, and ET were significantly higher when buserelin acetate was started in the midluteal phase. The live birth rates were also higher, but only significantly so for the rate per first treatment cycle. Conclusions: Clinical pregnancy and live birth rates are better when buserelin acetate is started in the midluteal phase rather than the early follicular phase before hMG and hCG stimulation in preparation for IVF-ET.

KW - Buserelin

KW - combined treatment

KW - early follicular phase administration

KW - GnRH analog

KW - IVF- ET

KW - midluteal phase administration

UR - http://www.scopus.com/inward/record.url?scp=0029997226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029997226&partnerID=8YFLogxK

M3 - Article

C2 - 8612858

AN - SCOPUS:0029997226

VL - 65

SP - 966

EP - 971

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -